SKYE — Skye Bioscience, Inc.

Open full analysis

Chart, dilution, float and news for SKYE in the TickerWise workspace.

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 16
• Website: https://skyebioscience.com

Latest SEC filings for SKYE

• 2026-10-14SCHEDULE 13G
• 2026-06-238-K
• 2026-05-298-K
• 2026-05-158-K
• 2026-05-1110-Q
• 2026-04-293
• 2026-04-16ARS
• 2026-04-068-K/A
• 2026-04-038-K
• 2026-03-198-K

Open full analysis

Educational tool only — not investment advice.